Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61858366%3A_____%2F15%3AN0000002" target="_blank" >RIV/61858366:_____/15:N0000002 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10323626 RIV/00216208:11130/16:10323626 RIV/61384399:31160/16:00047407 RIV/00064203:_____/16:10323626 RIV/00064165:_____/16:10323626

Result on the web

<a href="http://dx.doi.org/10.3109/00365521.2015.1079924" target="_blank" >http://dx.doi.org/10.3109/00365521.2015.1079924</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/00365521.2015.1079924" target="_blank" >10.3109/00365521.2015.1079924</a>

Result language

angličtina

Original language name

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation

Original language description

Background: Discontinuation of anti-TNF therapy in patients with inflammatory bowel diseases (IBD) in remission remains a controversial issue. The aims of our study were to assess the proportion of patients who relapse after cessation of biological treatment, and to identify potential risk factors of disease relapse. Methods: Consecutive IBD patients who discontinued anti-TNF therapy in steroid-free clinical and endoscopic remission were prospectively followed. Multiple logistic regression and Cox proportional-hazards models were used to assess the predictors of disease relapse. Results: Seventy-eight IBD patients (Crohn’s disease, CD 61; ulcerative colitis, UC 17) were included and followed for a median of 30 months (range 7–47). A total of 32 (53%) CD patients and nine (53%) UC patients relapsed by the end of the follow-up with a median time to relapse of 8 months (range 1–25) in CD patients and 14 months (range 4–37) in UC patients, respectively. The cumulative probabilities of maintaining remission at 6, 12, and 24 months were 82%, 59%, and 51% in CD patients, and 77%, 77%, and 64% in UC patients, respectively. Survival of CD patients who were in deep remission (clinical and endoscopic healing; faecal calprotectin 5150 mg/kg; CRP 5 mg/l) was not better compared with those who did not fulfill these criteria. In multivariate models, only colonic CD protected patients from disease relapse. Conclusions: Approximately half of the IBD patients relapsed within 2 years after anti-TNF discontinuation. In CD patients, no difference between those who were or were not in deep remission was found. Colonic localization protected patients from relapse.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FE - Other fields of internal medicine

OECD FORD branch

—

Project

<a href="/en/project/NT14300" target="_blank" >NT14300: Aetiology, pathogenesis and clinical course of skin and immunopathological adverse events of biological therapy in inflammatory bowel disease</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Scandinavian Journal of Gastroenterology

ISSN

0036-5521

e-ISSN

—

Volume of the periodical

51

Issue of the periodical within the volume

2

Country of publishing house

CA - CANADA

Number of pages

7

Pages from-to

196-202

UT code for WoS article

000373776500009

EID of the result in the Scopus database

—